Georgia Melagraki

Dr. Georgia Melagraki

NovaMechanics Ltd, Nicosia, Cyprus

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VMVarnavas Mouchlis
Varnavas Mouchlis
Antreas AfantitisAntreas Afantitis
Antreas Afantitis
ASAngela Serra
Angela Serra
MFMichele Fratello
Michele Fratello
APAnastasios Papadiamantis
Anastasios Papadiamantis
GMGeorgia Melagraki
Georgia Melagraki
De novo drug design is a computational approach that generates novel molecular structures from atomic building blocks with no a priori relationships. Conventional methods include structure-based and ligand-based design, which depend on the properties of the active site of a biological target or its known active binders, respectively. Artificial intelligence, including ma-chine learning, is an emerging field that has positively impacted the drug discovery process. Deep reinforcement learning is a subdivision of machine learning that combines artificial neural networks with reinforcement-learning architectures. This method has successfully been em-ployed to develop novel de novo drug design approaches using a variety of artificial networks including recurrent neural networks, convolutional neural networks, generative adversarial networks, and autoencoders. This review article summarizes advances in de novo drug design, from conventional growth algorithms to advanced machine-learning methodologies and high-lights hot topics for further development.

1 July 2009 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GMGeorgia Melagraki
Georgia Melagraki
Antreas AfantitisAntreas Afantitis
Antreas Afantitis
OIOlga Igglessi-Markopoulou
Olga Igglessi-Markopoulou
Anastasia DetsiAnastasia Detsi
Anastasia Detsi
MKMaria Koufaki
Maria Koufaki
DHDimitra J. Hadjipavlou-Litina
Dimitra J. Hadjipavlou-Litina

31 August 2010 in Journal of Cheminformatics
Verified
Journal Article
Open access
PDF file
BHBarry Hardy
Barry Hardy
NDNicki Douglas
Nicki Douglas
CHChristoph Helma
Christoph Helma
MRMicha Rautenberg
Micha Rautenberg
Nina JeliazkovaNina Jeliazkova
Nina Jeliazkova
SESylvia Escher
Sylvia Escher
OpenTox provides an interoperable, standards-based Framework for the support of predictive toxicology data management, algorithms, modelling, validation and reporting. It is relevant to satisfying the chemical safety assessment requirements of the REACH legislation as it supports access to experimental data, (Quantitative) Structure-Activity Relationship models, and toxicological information through an integrating platform that adheres to regulatory requirements and OECD validation principles. Initial research defined the essential components of the Framework including the approach to data access, schema and management, use of controlled vocabularies and ontologies, architecture, web service and communications protocols, and selection and integration of algorithms for predictive modelling. OpenTox provides end-user oriented tools to non-computational specialists, risk assessors, and toxicological experts in addition to Application Programming Interfaces (APIs) for developers of new applications. OpenTox actively supports public standards for data representation, interfaces, vocabularies and ontologies, Open Source approaches to core platform components, and community-based collaboration approaches, so as to progress system interoperability goals.

20 April 2007 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Anastasia DetsiAnastasia Detsi
Anastasia Detsi
DBDionysia Bouloumbasi
Dionysia Bouloumbasi
KPKyriakos C. Prousis
Kyriakos C. Prousis
MKMaria Koufaki
Maria Koufaki
GAGiorgos Athanasellis
Giorgos Athanasellis
DHDimitra J. Hadjipavlou-Litina
Dimitra J. Hadjipavlou-Litina

18 August 2022 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
EWEwelina Wyrzykowska
Ewelina Wyrzykowska
Alicja MikołajczykAlicja Mikołajczyk
Alicja Mikołajczyk
Iseult LynchIseult Lynch
Iseult Lynch
Nina JeliazkovaNina Jeliazkova
Nina Jeliazkova
NKNikolay Kochev
Nikolay Kochev
Tomasz PuzynTomasz Puzyn
Tomasz Puzyn

1 February 2011 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Antreas AfantitisAntreas Afantitis
Antreas Afantitis
GMGeorgia Melagraki
Georgia Melagraki
Panayiotis KoutentisPanayiotis Koutentis
Panayiotis Koutentis
HSHaralambos Sarimveis
Haralambos Sarimveis
GKGeorge Kollias
George Kollias